CompletedNCT00981097
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AIDS Malignancy Consortium
- Principal Investigator
- Nina Wagner-Johnston, MDMallinckrodt Institute of Radiology at Washington University Medical Center
- Intervention
- polymerase chain reaction(genetic)
- Enrollment
- 52 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2013
Study locations (16)
- Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
- UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
- University of California at Davis Center for Aids Research and Education Services, Sacramento, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- University of Miami, Miami, Florida, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Boston University Cancer Research Center, Boston, Massachusetts, United States
- Mallinckrodt Institute of Radiology at Washington University Medical Center, St Louis, Missouri, United States
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia, Philadelphia, Pennsylvania, United States
- Thomas Street Health Center, Houston, Texas, United States
- Baylor University Medical Center - Houston, Houston, Texas, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · The Emmes Company, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00981097 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha